Zacks bdsi
9 Aug 2019 Giving Lenovo a boost are analysts at Zacks. NextEarnings reports: CommScope, BDSI, Liquidia, TransEnterix, Innovate Bio, Aerie, Chimerix, 13 hours ago According to Zacks, analysts expect that BRT Apartments will report full year sales Zacks' sales calculations are a mean average based on a survey of (NASDAQ:BDSI) Downgraded by Zacks Investment Research to Hold 13 hours ago According to Zacks, analysts expect that Sterling Bancorp will report full for the quarter, missing the Zacks' consensus estimate of $0.54 by ($0.02). (NASDAQ:BDSI) Downgraded by Zacks Investment Research to Hold View BioDelivery Sciences International, Inc. BDSI investment & stock information. Get the latest BioDelivery Sciences International, Inc. BDSI detailed stock quotes The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating: The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:
BioDelivery Sciences International (Nasdaq:BDSI) had its target price reduced by research analysts at HC Wainwright from $4.00 to $3.50 in a research report issued to clients and investors on Wednesday.
BDSI Description — BioDelivery Sciences International Inc BioDelivery Sciences International is a pharmaceutical company with a focus on patients living with chronic pain. Co. has built a portfolio of products utilizing its BioErodible MucoAdhesive drug delivery technology, and other drug-delivery technologies to develop and commercialize new applications of proven therapies aimed at 6/12/2019 · BDSI: Get the latest Biodelivery Sciences International stock price and detailed information including BDSI news, historical charts and realtime prices. 11/12/2019 · The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share. The specialty pharmaceutical company posted revenue of $30.3 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $28.9 million. BioDelivery Sciences International, Inc. BDSI reported loss of 10 cents per share for fourth-quarter 2018, meeting the Zacks Consensus Estimate. In the year-ago quarter, the company had recorded a loss of 29 cents per share. View Biodelivery Sciences International, Inc. BDSI investment & stock information. Get the latest Biodelivery Sciences International, Inc. BDSI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
BioDelivery Sciences International (BDSI) Beats Q3 Earnings and Revenue Estimates Zacks 04:01PM BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations GlobeNewswire
BioDelivery Sciences International (BDSI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
12/25/2019 · Right now, BDSI is averaging 1,414,321 shares for the last 20 days. Earnings Outlook. The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well.
雪球为您提供BioDelivery科学国际(BDSI)股票实时行情,资金流向,新闻资讯, 万美元，每股亏损5美分，较去年18的美分有明显进展，整体情况高于Zacks预期。5月6 27 Dec 2019 According to Zacks, analysts expect that BioDelivery Sciences BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly What are people saying about $BDSI? Zacks: Brokerages Expect BioDelivery Sciences International, Inc. $BDSI Will Post Earnings of $0.01 Per Share
6/28/2019 · Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.
Exploring BioDelivery Sciences International (NASDAQ:BDSI) stock? According to Zacks Investment Research, "BioDelivery reported encouraging first-quarter Current Technical Analysis and interactive chart for $BDSI stock / shares. Dec 4, Zacks.com featured highlights include: Sciences International, Air Industries, See BDSI's revenue, employees, and funding info on Owler, the world's largest PublicIndependent Company of NASDAQBDSI. October 18, 2019Zacks
Zacks Investment Research Page 2 www.zacks.com WHATS NEW Onsolis Approved On July 16, 2009, the U.S. Food and Drug Administration approved Onsolis for the management of breakthrough pain (BTP) in patients with cancer, ages 18 and older, who already use opioid pain medication around the clock